OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026

Barchart · 2d ago

NANTES, France, August 28, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today announced that the Company will host a webcast with international experts in Inflammatory Bowel Diseases (IBD) to discuss its lead asset lusvertikimab on September 2, 2026, at noon ET (6pm CET).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.